Skip to main content
Erschienen in: Annals of Surgical Oncology 8/2017

12.04.2017 | Gastrointestinal Oncology

Incidence and Prognostic Value of Metastases to “Posterior” and Para-aortic Lymph Nodes in Resectable Gastric Cancer

verfasst von: Daniele Marrelli, MD, Francesco Ferrara, MD, Simone Giacopuzzi, MD, Paolo Morgagni, MD, Alberto Di Leo, MD, Lorenzo De Franco, MD, Corrado Pedrazzani, MD, Luca Saragoni, MD, Giovanni De Manzoni, MD, Franco Roviello, MD, FACS

Erschienen in: Annals of Surgical Oncology | Ausgabe 8/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

The purpose of this retrospective study was to evaluate the incidence and prognostic value of metastases to “posterior” (8p, 12b/p, 13) and para-aortic lymph nodes in a large cohort of Western patients submitted to D2 plus lymphadenectomy.

Methods

Removal of “posterior” nodes was performed in 743 patients, and para-aortic lymphadenectomy in a subgroup of 390 patients. After lymph node mapping and retrieval on the fresh specimen, a median number of 41 total lymph nodes were analyzed. The median follow-up period was 37 months for the entire series and 68 months for survivors.

Results

Of 743 included patients, 23 (3.1%) had metastases in station 8p, 12 (1.6%) in station 12b/p, and 19 (2.6%) in station 13. On the whole, 47 of 743 patients (6.3%) had positive “posterior” nodes. Para-aortic metastases were present in 42 of 390 patients (10.8%). Metastases to “posterior” stations were significantly related to depth of invasion, number of positive nodes, and surgical radicality. Distal tumors showed higher trend to metastasize to “posterior” nodes than upper third, whereas for para-aortic metastases it was the reverse. 5-year survival in patients with positivity to “posterior” nodes was 17%, with no significant difference according to 8p, 12b/p, and 13 stations; long-term outcome was overlapping to pN3b stage. 5-year survival in para-aortic positive cases was 11%, and a trend to better outcome was observed in proximal tumors.

Conclusions

Although metastases to “posterior” and para-aortic nodes are expression of an advanced nodal stage, not negligible survival rates are observed in subgroups of patients.
Literatur
1.
Zurück zum Zitat Han DS, Suh YS, Kong SH, et al. Nomogram predicting long-term survival after d2 gastrectomy for gastric cancer. J Clin Oncol. 2012;30:3834–40.CrossRefPubMed Han DS, Suh YS, Kong SH, et al. Nomogram predicting long-term survival after d2 gastrectomy for gastric cancer. J Clin Oncol. 2012;30:3834–40.CrossRefPubMed
2.
Zurück zum Zitat Marrelli D, Morgagni P, de Manzoni G, et al. External validation of a score predictive of recurrence after radical surgery for non-cardia gastric cancer: results of a follow-up study. J Am Coll Surg. 2015;221:280–90.CrossRefPubMed Marrelli D, Morgagni P, de Manzoni G, et al. External validation of a score predictive of recurrence after radical surgery for non-cardia gastric cancer: results of a follow-up study. J Am Coll Surg. 2015;221:280–90.CrossRefPubMed
3.
Zurück zum Zitat Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999;340:908–14.CrossRefPubMed Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999;340:908–14.CrossRefPubMed
4.
Zurück zum Zitat Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Br J Cancer. 1999;79:1522–30.CrossRefPubMedPubMedCentral Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Br J Cancer. 1999;79:1522–30.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11:439–49.CrossRefPubMed Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11:439–49.CrossRefPubMed
6.
Zurück zum Zitat de Steur WO, Hartgrink HH, Dikken JL, Putter H, van de Velde CJ. Quality control of lymph node dissection in the Dutch gastric cancer trial. Br J Surg. 2015;102:1388–93.CrossRefPubMed de Steur WO, Hartgrink HH, Dikken JL, Putter H, van de Velde CJ. Quality control of lymph node dissection in the Dutch gastric cancer trial. Br J Surg. 2015;102:1388–93.CrossRefPubMed
7.
Zurück zum Zitat Wu CW, Hsiung CA, Lo SS, et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol. 2006;7:309–15.CrossRefPubMed Wu CW, Hsiung CA, Lo SS, et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol. 2006;7:309–15.CrossRefPubMed
8.
Zurück zum Zitat Degiuli M, Sasako M, Ponti A, et al. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. Br J Surg. 2014;101:23–31.CrossRefPubMed Degiuli M, Sasako M, Ponti A, et al. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. Br J Surg. 2014;101:23–31.CrossRefPubMed
9.
Zurück zum Zitat Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20:1–19.CrossRef Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20:1–19.CrossRef
10.
Zurück zum Zitat Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D; ESMO Guidelines Committee. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v38–49.CrossRefPubMed Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D; ESMO Guidelines Committee. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v38–49.CrossRefPubMed
11.
Zurück zum Zitat Lee JH, Kim JG, Jung HK, et al. Clinical practice guidelines for gastric cancer in Korea: an evidence-based approach. J Gastric Cancer. 2014;14:87–104. Lee JH, Kim JG, Jung HK, et al. Clinical practice guidelines for gastric cancer in Korea: an evidence-based approach. J Gastric Cancer. 2014;14:87–104.
12.
Zurück zum Zitat De Manzoni G, Marrelli D, Baiocchi GL, et al. The Italian Research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer staging and treatment: 2015. Gastric Cancer. 2017;20:20–30.CrossRefPubMed De Manzoni G, Marrelli D, Baiocchi GL, et al. The Italian Research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer staging and treatment: 2015. Gastric Cancer. 2017;20:20–30.CrossRefPubMed
13.
Zurück zum Zitat Sasako M, Sano T, Yamamoto S, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359:453–62.CrossRefPubMed Sasako M, Sano T, Yamamoto S, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359:453–62.CrossRefPubMed
14.
Zurück zum Zitat Tokunaga M, Ohyama S, Hiki N, Fukunaga T, Aikou S, Yamaguchi T. Can superextended lymph node dissection be justified for gastric cancer with pathologically positive para-aortic lymph nodes? Ann Surg Oncol. 2010;17:2031–6.CrossRefPubMed Tokunaga M, Ohyama S, Hiki N, Fukunaga T, Aikou S, Yamaguchi T. Can superextended lymph node dissection be justified for gastric cancer with pathologically positive para-aortic lymph nodes? Ann Surg Oncol. 2010;17:2031–6.CrossRefPubMed
15.
Zurück zum Zitat Roviello F, Pedrazzani C, Marrelli D, et al. Super-extended (D3) lymphadenectomy in advanced gastric cancer. Eur J Surg Oncol. 2010;36:439–46.CrossRefPubMed Roviello F, Pedrazzani C, Marrelli D, et al. Super-extended (D3) lymphadenectomy in advanced gastric cancer. Eur J Surg Oncol. 2010;36:439–46.CrossRefPubMed
16.
Zurück zum Zitat Hasegawa S, Yoshikawa T, Rino Y, et al. Priority of lymph node dissection for Siewert type II/III adenocarcinoma of the esophagogastric junction. Ann Surg Oncol. 2013;20:4252–9.CrossRefPubMed Hasegawa S, Yoshikawa T, Rino Y, et al. Priority of lymph node dissection for Siewert type II/III adenocarcinoma of the esophagogastric junction. Ann Surg Oncol. 2013;20:4252–9.CrossRefPubMed
17.
Zurück zum Zitat Eom BW, Joo J, Kim YW, et al. Is there any role of additional retropancreatic lymph node dissection on D2 gastrectomy for advanced gastric cancer? Ann Surg Oncol. 2013;20:2669–75.CrossRefPubMed Eom BW, Joo J, Kim YW, et al. Is there any role of additional retropancreatic lymph node dissection on D2 gastrectomy for advanced gastric cancer? Ann Surg Oncol. 2013;20:2669–75.CrossRefPubMed
18.
Zurück zum Zitat Kodera Y, Kobayashi D, Tanaka C, Fujiwara M. Gastric adenocarcinoma with para-aortic lymph node metastasis: a borderline resectable cancer? Surg Today. 2015;45(9):1082–90.CrossRefPubMed Kodera Y, Kobayashi D, Tanaka C, Fujiwara M. Gastric adenocarcinoma with para-aortic lymph node metastasis: a borderline resectable cancer? Surg Today. 2015;45(9):1082–90.CrossRefPubMed
19.
Zurück zum Zitat Morita S, Fukagawa T, Fujiwara H, Katai H. The clinical significance of para-aortic nodal dissection for advanced gastric cancer. Eur J Surg Oncol. 2016;42:1448–54.CrossRefPubMed Morita S, Fukagawa T, Fujiwara H, Katai H. The clinical significance of para-aortic nodal dissection for advanced gastric cancer. Eur J Surg Oncol. 2016;42:1448–54.CrossRefPubMed
20.
Zurück zum Zitat Marrelli D, Pedrazzani C, Neri A, Corso G, DeStefano A, Pinto E, Roviello F. Complications after extended (D2) and superextended (D3) lymphadenectomy for gastric cancer: analysis of potential risk factors. Ann Surg Oncol. 2007;14:25–33.CrossRefPubMed Marrelli D, Pedrazzani C, Neri A, Corso G, DeStefano A, Pinto E, Roviello F. Complications after extended (D2) and superextended (D3) lymphadenectomy for gastric cancer: analysis of potential risk factors. Ann Surg Oncol. 2007;14:25–33.CrossRefPubMed
21.
Zurück zum Zitat Marrelli D, Mazzei MA, Pedrazzani C, et al. High accuracy of multislices computed tomography (MSCT) for para-aortic lymph node metastases from gastric cancer: a prospective single-center study. Ann Surg Oncol. 2011;18:2265–72.CrossRefPubMed Marrelli D, Mazzei MA, Pedrazzani C, et al. High accuracy of multislices computed tomography (MSCT) for para-aortic lymph node metastases from gastric cancer: a prospective single-center study. Ann Surg Oncol. 2011;18:2265–72.CrossRefPubMed
22.
Zurück zum Zitat Di Leo A, Marrelli D, Roviello F, et al. Lymph node involvement in gastric cancer for different tumor sites and T stage: Italian Research Group for Gastric Cancer (IRGGC) experience. J Gastrointest Surg. 2007;11:1146-53.CrossRefPubMed Di Leo A, Marrelli D, Roviello F, et al. Lymph node involvement in gastric cancer for different tumor sites and T stage: Italian Research Group for Gastric Cancer (IRGGC) experience. J Gastrointest Surg. 2007;11:1146-53.CrossRefPubMed
23.
Zurück zum Zitat Verlato G, Roviello F, Marchet A, Giacopuzzi S, Marrelli D, Nitti D, de Manzoni G. Indexes of surgical quality in gastric cancer surgery: experience of an Italian network. Ann Surg Oncol. 2009;16:594-602.CrossRefPubMed Verlato G, Roviello F, Marchet A, Giacopuzzi S, Marrelli D, Nitti D, de Manzoni G. Indexes of surgical quality in gastric cancer surgery: experience of an Italian network. Ann Surg Oncol. 2009;16:594-602.CrossRefPubMed
24.
Zurück zum Zitat Marrelli D, Morgagni P, de Manzoni G, et al. Prognostic value of the 7th AJCC/UICC TNM classification of noncardia gastric cancer: analysis of a large series from specialized Western centers. Ann Surg. 2012;255:486–91. Marrelli D, Morgagni P, de Manzoni G, et al. Prognostic value of the 7th AJCC/UICC TNM classification of noncardia gastric cancer: analysis of a large series from specialized Western centers. Ann Surg. 2012;255:486–91.
25.
Zurück zum Zitat Sasako M, McCulloch P, Kinoshita T, Maruyama K. New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. Br J Surg. 1995;82:346–51.CrossRefPubMed Sasako M, McCulloch P, Kinoshita T, Maruyama K. New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. Br J Surg. 1995;82:346–51.CrossRefPubMed
26.
Zurück zum Zitat Lee SL, Lee HH, Ko YH, Song KY, Park CH, Jeon HM, Kim SS. Relevance of hepatoduodenal ligament lymph nodes in resectional surgery for gastric cancer. Br J Surg. 2014;101:518–22.CrossRefPubMed Lee SL, Lee HH, Ko YH, Song KY, Park CH, Jeon HM, Kim SS. Relevance of hepatoduodenal ligament lymph nodes in resectional surgery for gastric cancer. Br J Surg. 2014;101:518–22.CrossRefPubMed
27.
Zurück zum Zitat Tsuburaya A, Mizusawa J, Tanaka Y, Fukushima N, Nashimoto A, Sasako M, Stomach Cancer Study Group of the Japan Clinical Oncology Group. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg. 2014;101:653–60.CrossRefPubMed Tsuburaya A, Mizusawa J, Tanaka Y, Fukushima N, Nashimoto A, Sasako M, Stomach Cancer Study Group of the Japan Clinical Oncology Group. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg. 2014;101:653–60.CrossRefPubMed
28.
Zurück zum Zitat Xue L, Chen XL, Zhang WH, et al. Risk factors and prognostic significance of retropancreatic lymph nodes in gastric adenocarcinoma. Gastroenterol Res Pract. 2015;2015:367679.CrossRefPubMedPubMedCentral Xue L, Chen XL, Zhang WH, et al. Risk factors and prognostic significance of retropancreatic lymph nodes in gastric adenocarcinoma. Gastroenterol Res Pract. 2015;2015:367679.CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Shen DF, Chen DW, Quan ZW, et al. Dissection of No. 13 lymph node in radical gastrectomy for gastric carcinoma. World J Gastroenterol. 2008;14:936–8.CrossRefPubMedPubMedCentral Shen DF, Chen DW, Quan ZW, et al. Dissection of No. 13 lymph node in radical gastrectomy for gastric carcinoma. World J Gastroenterol. 2008;14:936–8.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Wei ZW, Xia GK, Wu Y, Schwarz RE, Smith DD, He YL, Zhang CH. Evaluation of skeletonization of the hepatoduodenal ligament for the lower third gastric cancer by propensity score analysis. Hepatogastroenterology. 2013;60:1789-96.PubMed Wei ZW, Xia GK, Wu Y, Schwarz RE, Smith DD, He YL, Zhang CH. Evaluation of skeletonization of the hepatoduodenal ligament for the lower third gastric cancer by propensity score analysis. Hepatogastroenterology. 2013;60:1789-96.PubMed
31.
Zurück zum Zitat Imamura T, Komatsu S, Ichikawa D, et al. Clinical characteristics of hepatoduodenal lymph node metastasis in gastric cancer. World J Gastroenterol. 2015;21:10866-73.CrossRefPubMedPubMedCentral Imamura T, Komatsu S, Ichikawa D, et al. Clinical characteristics of hepatoduodenal lymph node metastasis in gastric cancer. World J Gastroenterol. 2015;21:10866-73.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Tokunaga M, Ohyama S, Hiki N, et al. Therapeutic value of lymph node dissection in advanced gastric cancer with macroscopic duodenum invasion: is the posterior pancreatic head lymph node dissection beneficial? Ann Surg Oncol. 2009;16:1241–6.CrossRefPubMed Tokunaga M, Ohyama S, Hiki N, et al. Therapeutic value of lymph node dissection in advanced gastric cancer with macroscopic duodenum invasion: is the posterior pancreatic head lymph node dissection beneficial? Ann Surg Oncol. 2009;16:1241–6.CrossRefPubMed
33.
Zurück zum Zitat de Manzoni G, Di Leo A, Roviello F, Marrelli D, Giacopuzzi S, Minicozzi AM, Verlato G. Tumor site and perigastric nodal status are the most important predictors of para-aortic nodal involvement in advanced gastric cancer. Ann Surg Oncol. 2011;18:2273–80.CrossRefPubMed de Manzoni G, Di Leo A, Roviello F, Marrelli D, Giacopuzzi S, Minicozzi AM, Verlato G. Tumor site and perigastric nodal status are the most important predictors of para-aortic nodal involvement in advanced gastric cancer. Ann Surg Oncol. 2011;18:2273–80.CrossRefPubMed
34.
Zurück zum Zitat Junfeng Z, Yingxue H, Peiwu Y. Systematic review of risk factors for metastasis to para-aortic lymph nodes in gastric cancer. Surg Oncol. 2013;22:210–6.CrossRefPubMed Junfeng Z, Yingxue H, Peiwu Y. Systematic review of risk factors for metastasis to para-aortic lymph nodes in gastric cancer. Surg Oncol. 2013;22:210–6.CrossRefPubMed
35.
Zurück zum Zitat de Manzoni G, Verlato G, Bencivenga M, et al. Impact of super-extended lymphadenectomy on relapse in advanced gastric cancer. Eur J Surg Oncol. 2015;41:534–40.CrossRefPubMed de Manzoni G, Verlato G, Bencivenga M, et al. Impact of super-extended lymphadenectomy on relapse in advanced gastric cancer. Eur J Surg Oncol. 2015;41:534–40.CrossRefPubMed
36.
Zurück zum Zitat Marrelli D, Polom K, de Manzoni G, Morgagni P, Baiocchi GL, Roviello F. Multimodal treatment of gastric cancer in the west: Where are we going? World J Gastroenterol. 2015;21:7954–69.CrossRefPubMedPubMedCentral Marrelli D, Polom K, de Manzoni G, Morgagni P, Baiocchi GL, Roviello F. Multimodal treatment of gastric cancer in the west: Where are we going? World J Gastroenterol. 2015;21:7954–69.CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Marrelli D, Pedrazzani C, Morgagni P, et al; Italian Research Group for Gastric Cancer. Changing clinical and pathological features of gastric cancer over time. Br J Surg. 2011;98:1273–83.CrossRefPubMed Marrelli D, Pedrazzani C, Morgagni P, et al; Italian Research Group for Gastric Cancer. Changing clinical and pathological features of gastric cancer over time. Br J Surg. 2011;98:1273–83.CrossRefPubMed
Metadaten
Titel
Incidence and Prognostic Value of Metastases to “Posterior” and Para-aortic Lymph Nodes in Resectable Gastric Cancer
verfasst von
Daniele Marrelli, MD
Francesco Ferrara, MD
Simone Giacopuzzi, MD
Paolo Morgagni, MD
Alberto Di Leo, MD
Lorenzo De Franco, MD
Corrado Pedrazzani, MD
Luca Saragoni, MD
Giovanni De Manzoni, MD
Franco Roviello, MD, FACS
Publikationsdatum
12.04.2017
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 8/2017
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-017-5857-8

Weitere Artikel der Ausgabe 8/2017

Annals of Surgical Oncology 8/2017 Zur Ausgabe

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 Ablationstherapie Nachrichten

Nach der Katheterablation von Vorhofflimmern kommt es bei etwa einem Drittel der Patienten zu Rezidiven, meist binnen eines Jahres. Wie sich spätere Rückfälle auf die Erfolgschancen einer erneuten Ablation auswirken, haben Schweizer Kardiologen erforscht.

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 Appendizitis Nachrichten

Schmerzen im Unterbauch, aber sonst nicht viel, was auf eine Appendizitis hindeutete: Ein junger Mann hatte Glück, dass trotzdem eine Laparoskopie mit Appendektomie durchgeführt und der Wurmfortsatz histologisch untersucht wurde.

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

23.04.2024 Operationsvorbereitung Nachrichten

Derzeit wird empfohlen, eine Therapie mit GLP-1-Rezeptoragonisten präoperativ zu unterbrechen. Eine neue Studie nährt jedoch Zweifel an der Notwendigkeit der Maßnahme.

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 EAU 2024 Kongressbericht

Die Ureterstriktur ist eine relativ seltene Komplikation, trotzdem bedarf sie einer differenzierten Versorgung. In komplexen Fällen wird dies durch die roboterassistierte OP-Technik gewährleistet. Erste Resultate ermutigen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.